Business
Falcon Technologies Announces Its Participation and Attendance at the May 31, 2019 Food and Drug Administration Meeting for Products Containing Cannabis and Cannabis-Derived Compounds
Falcon Technologies Announces Its Participation and Attendance at the May 31, 2019 Food and Drug Administration Meeting for Products Containing Cannabis and Cannabis-Derived Compounds.
About this update from Eco-growth Strategies Inc.
[{"type":"text","content":"SACRAMENTO, CA / ACCESSWIRE / May 15, 2019 / Falcon Technologies, Inc. (OTC PINK: FLCN) announced today that a representative for Falcon Technologies, Inc. will be attending the May 31st Food and Drug Administration meeting for scientific data and information about products containing cannabis and cannabis-derived compounds.Falcon Technologies is a public company focused on the marketing, sale, and distribution of CBD products and products derived from industrial hemp. According to the Food and Drug Administration, the goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products. Falcon Technologies is proud to be a participant at this historic meeting of the United States Food and Drug Administration.The Agriculture Improvement Act of 2018, Public Law 115-334 (the 2018 Farm Bill), which, among other things removed the plant Cannabis sativa L. or "hemp" from the Controlled Substances Act has dramatically increased the need for CBD science and and to educate the public on CBD products such as the ones Falcon are developing. The 2018 Farm Bill has also dramatically increased the demand for hemp-derived products. Falcon is 100 percent focused on the development, marketing and sale of CBD products and hemp-derived products.Many of the participants at the FDA meeting will be leaders in the CBD industry, leading scientists, leading medical doctors and political heavyweights who have been instrumental in the legalization of the industrial hemp and the products derived from hemp including hemp protein, hemp oil and hemp seeds.William J. Delgado, Chairman and Chief Executive Officer of Falcon Technologies stated, "We are excited Falcon will be represented at this very important meeting. The FDA understands the importance of CBD but also understands the importance of regulating CBD and other hemp-derived products."CBD (Cannabidiol) is one of at least 80 active cannabinoids identified in both cannabis and industrial hemp. It is a major constituent of both plants, although the percentages of total composition can vary greatly from strain to strain. Unlike THC (the other prevalent cannabinoid), CBD is non-psychoactive while having the potential to possess ...